Results to your Biomarker

At the forefront of scientific development, ABF is leading the way with innovative methods for the accurate analysis of cannabis and cannabinoids. Risk assessment of these new products using appropriate biomarkers is becoming increasingly important, particularly for pharmacokinetic (PK) and toxicokinetic (TK) studies, exposure assessment and risk evaluation. Our CBD and THC PK/TK assay runs according to GLP and GCP as part of our GLP-certified method portfolio. Our aim is to support you responsibly in the introduction of new products. ABF is your partner for reliable and innovative cannabinoid bioanalysis.